InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Positive Phase 1 Safety Results for Lucid-MS
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that its Australian subsidiary has received the clinical study report for a Phase 1 multiple ascending dose trial of Lucid-MS. The report confirmed no safety or tolerability concerns in healthy participants. Lucid-MS is a patented, first-in-class, non-immunomodulatory neuroprotective compound targeting multiple sclerosis by preventing demyelination. The results support advancement to efficacy trials in MS patients and preparation for an…